Haemonetics (NYSE:HAE) shares dipped slightly before hours on third-quarter results that were mixed compared to the consensus forecast.
The Boston-based company posted profits of $23.2 million, or 45¢ per share, on sales of $259.8 million for the three months ended Jan. 1, 2022, for a 27.1% bottom-line slide on sales growth of 8.1%.
Adjusted to exclude one-time items, earnings per share were 84¢, 11¢ ahead of Wall Street, where analysts were looking for sales of $266.7 million.
“Our third-quarter results reflect our agility and resilience in meeting the challenges of the pandemic on U.S. blood and plasma collections and some hospital products,” Haemonetics CEO Chris Simon said in a news release. “Plasma collections improved and we continued to convert customers to our latest NexSys and Persona technologies, while our hospital business delivered double-digit growth and a new record quarter for sales in hemostasis management and vascular closure. Our operational excellence program continues to strengthen our manufacturing and supply capabilities, contributing to significantly improved gross margins and partially offsetting COVID-related pressures.”
Haemonetics tightened its previously announced adjusted EPS guidance from between $2.40 and $2.65 to between $2.45 and $2.55. The company also lessened its organic revenue guidance, dropping it from a range of 7% to 10% down to between 5% and 7%.
HAE shares were down 1.3% at $46.37 per share before the market opened today.